Preparation Of Compound Moxidectin Preparation And Its Clinical Application In Feline Ear Mite Disease

Animal parasitic diseases can cause serious harm to the health of animals and people,and it is difficult to completely eliminate the occurrence of the disease.At present,animal parasitic diseases are mainly controlled by the use of chemical drugs.Although the drugs have good effects in controlling parasitic diseases,due to the widespread use of such drugs and the lack of standardization in their actual use,the resistance rate of parasites to such drugs has increased.The therapeutic and preventive effect of the drug declines,the duration of the drug is shortened,the drug is administered frequently,the drug effect is reduced,and a vicious circle is entered,and finally no drug is available.Therefore,the research and development of long-acting and sustained-release preparations of antiparasitic drugs and the strict implementation of scientific and standardized drug use procedures are of great significance to the control of animal parasitic diseases.Moxidectin is a macrolide antibiotic with low toxicity,high efficiency and broad spectrum.Imidacloprid belongs to the neonicotinoid class of insecticides and is widely used in veterinary medicine worldwide due to its selective toxicity to insects and its safety to mammals.The combination of the two drugs can simultaneously expel a variety of parasites in and out of the body,which makes the use of deworming drugs more convenient.In this study,transdermal administration was selected as the mode of administration,and chemical penetration enhancers were used to meet the needs of drug transdermal,so that the preparation had the advantages of simple manufacturing process,convenient administration,and small adverse reactions.In this study,a high-performance liquid chromatography detection method for moxidectin was established,and the regression equation was obtained:A=24327449C+106309,R~2=0.9999;the recovery rate was 96.65-98.85%;the intra-day precision was 1.02%,and the inter-day precision was 1.15 %.The formulations were screened by orthogonal test and in vitro transdermal test,and the 4-element permeationpromoting system of compound moxidectin was screened out,A1 concentration azone,B1 concentration isopropyl myristate,C1 concentration propylene glycol,D1 concentration dimethyl methacrylate base sulfoxide,and a compound moxidectin preparation was prepared.The in vitro drug release test of the preparation was carried out by the method of in vitro transdermal test.The experimental results showed that the preparation in this study had no sudden release phenomenon within 0.5 h at the beginning of the experiment;The cumulative release rate of the research preparation was 46.9%,and it was finally released completely within 72 h.This result proves that the sustained release effect of the formulation in this study is good and better than that of the commercial formulation.In this study,the skin irritation of the preparation was investigated.The preparation in this study only caused mild erythema on the skin of experimental animals at 1 hour,and the skin irritation intensity was 0.2（0-0.5,no irritation）,indicating that the irritation of the preparation in this study is in line with clinical application.Requirements for the safety of the preparation;the stability of the preparation was investigated through the influence factor test and accelerated testing.Under the condition of high temperature environment of 60℃,the content of moxidectin decreased to 63.87% of the initial content after 10 days,and the content of imidacloprid decreased to 92.43% of the initial content;the high temperature environment of 40℃,the content of moxidectin decreased to the initial content after 10 days The content of imidacloprid was reduced to 97.20% of the initial content.After 12 days under low temperature test conditions,the content of moxidectin decreased to 87.10% of the initial content,and the content of imidacloprid decreased to 96.17% of the initial content.Under light conditions for4500±500 lx10 days,the content of moxidectin decreased to 89.70% of the initial content,and the content of imidacloprid decreased to 97.34% of the initial content.After being placed under accelerated test conditions for 3 months,the content of moxidectin decreased to 93.50% of the initial content,and the content of imidacloprid did not decrease significantly;see significant reduction.It is suggested that environmental conditions such as high temperature and strong light irradiation should be avoided during preparation,storage and transportation of the preparation.In this study,the clinical application effect of the preparation was investigated through the treatment and prevention of cat ear mite disease.Administered to cats at a dose of 1 mg/kg,the results show that the preparation has good preventive and therapeutic effects of ear mites and has a long-lasting effect;the prevention and control efficiency of cat ear mites is 100%,the cure rate is 93.33%.In conclusion,the compound moxidectin preparation developed in this study is convenient to use,safe to operate,and has good medicinal effect.It can be used as a safe and efficient anthelmintic preparation.